Rockwell Medical (RMTI) Depreciation & Amortization (CF) (2010 - 2026)
Rockwell Medical (RMTI) posted Depreciation & Amortization (CF) of $511000.0 for Q1 2026, down 6.41% on a QoQ basis from $546000.0 in Q4 2025, and down 5.19% year-over-year from $539000.0 in Q1 2025.
Rockwell Medical (RMTI) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Rockwell Medical's Depreciation & Amortization (CF) history runs 17 years deep, the most recent figure standing at $511000.0 for Q1 2026.
- Quarterly Depreciation & Amortization (CF) fell 5.19% year-over-year to $511000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.2 million (changed 0.46% YoY) and the FY2025 annual result came in at $2.2 million, up 0.55% from the prior year.
- Depreciation & Amortization (CF) was $511000.0 for Q1 2026 at Rockwell Medical, down from $546000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $564000.0 in Q3 2023 and bottomed at $138000.0 in Q1 2022.
- A 5-year average of $406058.8 and a median of $543000.0 in 2024 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) sank 31.68% — and 2023, when it surged 294.41%.
- Rockwell Medical's Depreciation & Amortization (CF) stood at $154000.0 in 2022, then surged by 257.14% to $550000.0 in 2023, then slipped by 1.27% to $543000.0 in 2024, then rose by 0.55% to $546000.0 in 2025, then dropped by 6.41% to $511000.0 in 2026.
- Business Quant data shows RMTI's Depreciation & Amortization (CF) at $511000.0 in Q1 2026, $546000.0 in Q4 2025, and $544000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 239.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 119.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.04 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 22.60 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 676.10 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 7.20 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 172.00 Mn |
| 10 | Rockwell Medical | 25.77 Mn | 1.88 Mn | 2.90 Mn | 511,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 511,000.00 |
| Mar 31, 2026 | 511,000.00 |
| Dec 31, 2025 | 546,000.00 |
| Dec 31, 2025 | 546,000.00 |
| Sep 30, 2025 | 544,000.00 |
| Sep 30, 2025 | 544,000.00 |
| Jun 30, 2025 | 563,000.00 |
| Jun 30, 2025 | 563,000.00 |
| Mar 31, 2025 | 539,000.00 |
| Mar 31, 2025 | 539,000.00 |
| Dec 31, 2024 | 543,000.00 |
| Dec 31, 2024 | 543,000.00 |
| Sep 30, 2024 | 543,000.00 |
| Sep 30, 2024 | 543,000.00 |
| Jun 30, 2024 | 549,000.00 |
| Jun 30, 2024 | 549,000.00 |
| Mar 31, 2024 | 545,000.00 |
| Mar 31, 2024 | 545,000.00 |
| Dec 31, 2023 | 550,000.00 |
| Dec 31, 2023 | 550,000.00 |